Clinical trials: Weight Loss Trial
Obesity
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
The study evaluated the safety and efficacy of the vBloc Therapy delivered by the Maestro Rechargeable System compared to a sham control for the treatment obesity.
- Trial name
- ReCharge (NCT01327976)
- Testing
- vBloc (Active Device)
- Where
- 10 sites in United States, Australia
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Dementia
Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients
The purpose of this study is to demonstrate the efficacy of megestrol acetate in the gain of body weight in patients with primary or mixed Dementia with a weight loss.
- Trial name
- NCT00503516
- Testing
- Megestrol acetate
- Where
- Spain
- Volunteers
- 39 people
- Sponsor
- Rottapharm Spain
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight (BMI > 25)
AIM-WEIGHT: AI-Guided Microbiome-Targeted Nutritional Intervention for Weight Loss
AIM-WEIGHT is a clinical study evaluating whether a fixed microbiome-targeted nutritional supplement can support weight loss in adults with overweight or obesity who do not have prediabetes or diabetes.
- Trial name
- AIM-WEIGHT (NCT07736547)
- Testing
- AI-Guided Microbiome-Targeted Nutritional Supplement, Lifestyle counselling
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Varol TUNALI
PreDiabetes
Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program
This study will test the weight loss efficacy of a mobile diabetes prevention program intervention. Half of the sample of prediabetic adults will receive the virtual DPP and half will receive usual medical care.
- Trial name
- NCT03865342
- Testing
- Noom Coach DPP
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Noom Inc.
Overweight, Obesity
Food, Activity and Behavior Trial
This study will provide data on the response over 24 months to two commercial weight loss programs (center-based and telephone-based) compared to control conditions.
- Trial name
- FAB (NCT00640900)
- Testing
- Usual care, Commercial weight loss program
- Where
- United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Jenny Craig, Inc.
Functional Gastrointestinal Disorders (FGIDs), Weight Loss
Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates
Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and…
- Trial name
- NCT07320287
- Testing
- RO water, LiveSpo PREG-MOM, LiveSpo CONSY
- Where
- Vietnam
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Anabio R&D
Obesity
Study for Short Term Weight Loss in Candidates for Bariatric Surgery
The purpose of this study is to determine whether the GI Endobarrier Liner is safe and effective.
- Trial name
- NCT00985491
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 46 people
- Sponsor
- Morphic Medical Inc.
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Obesity
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause.
- Trial name
- NCT07850050
- Testing
- Survodutide
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Obesity
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.
- Trial name
- NCT01666691
- Testing
- Beloranib
- Where
- 3 sites in Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Weight Loss
Evaluating the Occurrence of Participation Trends Among Weight Loss Clinical Trials Patients
Clinical studies, with a distinct focus on weight loss, play a crucial role in evaluating the safety and effectiveness of novel treatments.
- Trial name
- NCT06155552
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Randomized Versus Placebo, Controlled
Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo
Clinical intervention on overweight or moderately obeses adults. The objective of this trial is to demonstrate the superior eficacy of Alphagos to placebo on weight loss during a low-calorie diet of 12 weeks.
- Conditions
- Randomized Versus Placebo, Controlled, Double Blind
- Trial name
- NCT02228746
- Testing
- Alpha-galacto-oligosaccharides
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Olygose
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.
- Trial name
- NCT00367783
- Testing
- CP-741,952
- Where
- 5 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer